¹⁸F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study.

ABSTRACT:

Background

Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. ¹⁸F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is an imaging modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as pancreatic ductal adenocarcinoma (PDAC). This phase I/II study aimed to assess the feasibility of ¹⁸F-PSMA PET/CT to detect PDAC.

Methods

Seventeen patients with clinically resectable PDAC underwent ¹⁸F-PSMA PET/CT prior to surgical resection. Images were analyzed both visually and (semi)quantitatively by deriving the maximum standardized u

SUBMITTER: Puik JR 

PROVIDER: S-EPMC11734402 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature